RT Journal Article
SR Electronic
T1 Model stability of COVID-19 mortality prediction with biomarkers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20161323
DO 10.1101/2020.07.29.20161323
A1 Chenyan Huang
A1 Xi Long
A1 Zhuozhao Zhan
A1 Edwin van den Heuvel
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.29.20161323.abstract
AB Coronavirus disease 2019 (COVID-19) is an unprecedented and fast evolving pandemic, which has caused a large number of critically ill patients and deaths globally. It is an acute public health crisis leading to overloaded critical care capacity. Timely prediction of the clinical outcome (death/survival) of hospital-admitted COVID-19 patients can provide early warnings to clinicians, allowing improved allocation of medical resources. In a recently published paper, an interpretable machine learning model was presented to predict the mortality of COVID-19 patients with blood biomarkers, where the model was trained and tested on relatively small data sets. However, the model or performance stability was not explored and assessed. By re-analyzing the data, we reveal that the reported mortality prediction performance was likely over-optimistic and its uncertainty was underestimated or overlooked, with a large variability in predicting deaths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used publicly available data and did not require additional IRB approval. The orignal study has been approved by Tongji Hospital Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly available data. The data were retrieved from the supplementary information of the published work by Yan et al. (https://doi.org/10.1038/s42256-020-0180-7) on May 16, 2020. https://static-content.springer.com/esm/art%3A10.1038%2Fs42256-020-0180-7/MediaObjects/42256_2020_180_MOESM3_ESM.zip